Exact Sciences sees $31.2M net loss in Q1: 5 notes


Although Exact Sciences saw an increase in revenue in the first quarter of 2021, it had a $31.2 million net loss.

Five takeaways from its financial results:

1. Revenue in the first quarter was $402.1 million, up 16 percent from the same period last year.

2. Net loss was $31.2 million, or $0.18 per share. 

3. Screening revenue, which includes Cologuard tests, increased 10 percent at $240.3 million.

4. Precision oncology revenue was $129.4 million, and COVID-19 testing revenue was $32.3 million.

5. The company expects revenue of $1.7 billion this year, with $1.1 billion of that coming from screening products this year.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers